1. Information about nitrosamine impurities in medications. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications.
2. FDA works to avoid shortage of sitagliptin following detection of nitrosamine impurity. Available from:https://www.fda.gov/drugs/drug-safety-and-availability/fda-works-avoid-shortage-sitagliptin-following-detection-nitrosamine-impurity.
3. Updates on possible mitigation strategies to reduce the risk of nitrosamine drug substance-related impurities in drug products. Available from:https://www.fda.gov/drugs/drug-safety-and-availability/updates-possible-mitigation-strategies-reduce-risk-nitrosamine-drug-substance-related-impurities.
4. Inhibition of N-nitrosamine formation in drug products: a model study;Nanda;J Pharm Sci,2021
5. Bumetanide as a model NDSRI substrate: N-nitrosobumetanide impurity formation and its inhibition in bumetanide tablets;Shakleya;J Pharm Sci,2023